PMID: 16506525Mar 2, 2006Paper

Novel immunotherapeutic approaches to glioma

Current Opinion in Molecular Therapeutics
Ryuya Yamanaka

Abstract

Despite advances in radiation, chemotherapy and surgical resectioning, the prognosis of patients with malignant glioma is poor. Therefore, the development of a new treatment modality is extremely important. There are an increasing number of reports that systemic immunotherapy using dendritic cells and peptides is capable of inducing an anti-glioma response. This review highlights progress in dendritic cell- and peptide-based immunotherapy for glioma patients. Dendritic cell- and peptide-based immunotherapy strategies appear promising as an approach to successfully induce an antitumor immune response and increase survival in patients with glioma; the therapy appears to be safe and without major side effects. Biotherapy for malignant glioma with dendritic cells and peptides represents a novel treatment paradigm.

Related Concepts

Related Feeds

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.

Related Papers

Brain and nerve = Shinkei kenkyū no shinpo
Ryuya Yamanaka, Kyogo Itoh
Expert Opinion on Biological Therapy
Ryuya Yamanaka, Kyogo Itoh
Nō to shinkei = Brain and nerve
Ryuya YamanakaRyuichi Tanaka
International Journal of Oncology
Ryuya YamanakaRyuichi Tanaka
© 2021 Meta ULC. All rights reserved